Karin Birgitta Margareta Ståhl
Operationeel Directeur bij Akinion Pharmaceuticals AB
Oorsprong van het eerstegraads netwerk van Karin Birgitta Margareta Ståhl
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Public Company | Pharmaceuticals: Major | 10 | |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Karin Birgitta Margareta Ståhl via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Affibody Medical AB
Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
The University of Liverpool
The University of Liverpool Other Consumer ServicesConsumer Services The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom. | College/University | Undergraduate Degree | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Wellcome Trust Technology Transfer
Wellcome Trust Technology Transfer Investment ManagersFinance Wellcome Trust Technology Transfer (Wellcome Trust Technology Transfer) is a venture capital subsidiary of The Wellcome Trust Ltd. founded in 1992 by Graham Eric Fagg. The firm is headquartered in London. | Investment Managers | Founder | |
Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree | |
BASF Performance Products Ltd. (United Kingdom)
BASF Performance Products Ltd. (United Kingdom) Chemicals: SpecialtyProcess Industries Basf Performance Products Ltd. manufactures chemical products. It offers dyes and pigments, plastics, and other inorganic basic chemicals. The company was founded on September 12, 1996 and is headquartered in Cheadle, the United Kingdom. | Chemicals: Specialty | Corporate Officer/Principal | |
GlaxoSmithKline, Inc.
GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Uppsala | College/University | Graduate Degree Doctorate Degree | |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chief Executive Officer Chief Executive Officer | |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Pharmaceuticals: Major | Director/Board Member | |
University of Stockholm | College/University | Masters Business Admin Undergraduate Degree | |
University College London | College/University | Doctorate Degree | |
Royal Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
University of Lund | College/University | Corporate Officer/Principal Graduate Degree | |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Investment Managers | Founder Investment Committee Member Private Equity Investor | |
Kernel Management Partners Ltd.
Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Investment Managers | Private Equity Investor | |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Biotechnology | Chairman | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
PROMIMIC AB | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
BIOARCTIC AB | Pharmaceuticals: Major | Director of Finance/CFO | |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
GlaxoSmithkline AB
GlaxoSmithkline AB Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AB is a company that manufactures pharmaceutical products. GlaxoSmithKline AB is based in Solna, Sweden. Founded in 1983. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roche AB
Roche AB Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Extenda AB
Extenda AB Information Technology ServicesTechnology Services Extenda AB develops point-of-sale technology (POS) solutions. Its product suite include transaction engine, selfscan, mobile POS, and self checkout. The firm also offers support, service and maintenance, and catalogue services. The company was founded by Peter Carlman in 1982 and is headquartered in Stockholm, Sweden. | Information Technology Services | Director of Finance/CFO | |
Sanofi Aventis AB
Sanofi Aventis AB Sanofi Aventis AB engages in the pharmaceutical industsry. The company is headquartered in Stockholm, Sweden. | Corporate Officer/Principal Corporate Officer/Principal | ||
CANTARGIA AB | Pharmaceuticals: Major | Director/Board Member | |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Comptroller/Controller/Auditor Corporate Officer/Principal | |
SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Chief Tech/Sci/R&D Officer Chief Executive Officer Director/Board Member Chairman General Counsel | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Director/Board Member | |
MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Biotechnology | Chairman Chairman Director/Board Member Director/Board Member | |
Celgene AB | Corporate Officer/Principal Corporate Officer/Principal | ||
DICOT PHARMA AB | Pharmaceuticals: Major | Director/Board Member | |
Oncopeptides Incentive AB | Director/Board Member Director/Board Member | ||
M Von Euler Consulting AB
M Von Euler Consulting AB Miscellaneous Commercial ServicesCommercial Services M Von Euler Consulting AB operates as a scientific and technical research & development organization. M Von Euler Consulting AB is based in Stockholm, Sweden. Curt Mikael von Euler-Chelpin has been the CEO of the Swedish company since 2014. | Miscellaneous Commercial Services | Chief Executive Officer | |
Bostadsrättsföreningen Mälarvik
Bostadsrättsföreningen Mälarvik Miscellaneous Commercial ServicesCommercial Services Bostadsrättsföreningen Mälarvik operates as a housing association. | Miscellaneous Commercial Services | Director/Board Member | |
Lisa Martin-Löf Konsultbyrå AB | Director/Board Member | ||
A3P Biomedical AB
A3P Biomedical AB Medical/Nursing ServicesHealth Services A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors. | Medical/Nursing Services | Director of Finance/CFO |
Statistieken
Internationaal
Zweden | 35 |
Verenigd Koninkrijk | 11 |
Canada | 3 |
Frankrijk | 2 |
Verenigde Staten | 2 |
Sectoraal
Health Technology | 25 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 6 |
Health Services | 3 |
Operationeel
Director/Board Member | 148 |
Corporate Officer/Principal | 78 |
Chairman | 41 |
Independent Dir/Board Member | 26 |
Chief Executive Officer | 24 |
Sterkste connecties
Insiders | |
---|---|
Viktor Drvota | 41 |
Cecilia Margaretha Daun-Wennborg | 31 |
Per Wold-Olsen | 25 |
Torsten Rüdiger Goesch | 23 |
Terje Kalland | 20 |
Michael Forer | 18 |
Curt Mikael von Euler-Chelpin | 17 |
Rein Piir | 16 |
Anders Martin-Löf | 16 |
Niclas Adler | 15 |
Graham Eric Fagg | 14 |
Maria Klockare | 13 |
Lars Abrahmsén | 11 |
Johan Dighed | 10 |
Luigi Costa | 10 |
- Beurs
- Insiders
- Karin Birgitta Margareta Ståhl
- Bedrijfsconnecties